









Markets
/
Stocks
/
nasdaq-sldb
/

Solid Biosciences Inc

SLDB

5.440USD

-0.030-0.55%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

422.16MMarket Cap

LossP/E TTM



Solid Biosciences Inc

5.440

-0.030-0.55%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

65 / 506

Overall Ranking

161 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 13 analysts

Buy

Current Rating

15.818

Target Price

+189.18%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. The Company also has two cardiac pipeline gene transfer programs, SGT-601 for TNNT2 DCM and SGT-701 for RBM20 DCM, that are both in early preclinical development. It also has a neuromuscular gene transfer program for the treatment of Friedreich's ataxia. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including novel capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 45.03.

Undervalued

The company’s latest PE is -1.95, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 81.08M shares, increasing 25.24% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 3.37M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.46.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 6.75, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.75

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.21

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.75

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -1.96, which is -67.72% below the recent high of -0.63 and 3.96% above the recent low of -1.88.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 65/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 8.77, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Solid Biosciences Inc is 16.00, with a high of 20.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.77

Change

Support & Resistance

No Data

Analyst Rating

Based on 13 analysts

Buy

Current Rating

15.818

Target Price

+189.18%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Solid Biosciences Inc

SLDB

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 7.11, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 6.07 and the support level at 4.87, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.11

Change

-0.04

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.038

Neutral

RSI(14)

45.942

Neutral

STOCH(KDJ)(9,3,3)

62.651

Neutral

ATR(14)

0.327

High Vlolatility

CCI(14)

43.651

Neutral

Williams %R

37.500

Buy

TRIX(12,20)

-0.556

Sell

StochRSI(14)

65.553

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

5.440

Buy

MA10

5.338

Buy

MA20

5.487

Sell

MA50

5.960

Sell

MA100

4.925

Buy

MA200

4.535

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 104.59%, representing a quarter-over-quarter increase of 1.53%. The largest institutional shareholder is The Vanguard, holding a total of 3.37M shares, representing 4.32% of shares outstanding, with 23.24% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Perceptive Advisors LLC

11.91M

Bain Capital Life Sciences Investors, LLC

7.91M

+57.15%

Invus Public Equities Advisors, LLC

7.42M

+97.81%

Adage Capital Management, L.P.

6.73M

+284.96%

RA Capital Management, LP

4.33M

+2.14%

BlackRock Institutional Trust Company, N.A.

1.92M

+11.83%

The Vanguard Group, Inc.

Star Investors

2.46M

+75.59%

Fidelity Management & Research Company LLC

3.52M

+7432.14%

Citadel Advisors LLC

1.89M

+98.85%

Monashee Investment Management, LLC

1.67M

+248.63%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.13, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 2.52. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.